Table 1.
Market shares for the status quo and the new projections scenarios
| Scenarios | BoNT-A treatment | Year 1
|
Year 2
|
Year 3
|
Year 4
|
Year 5
|
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion of patients eligible | Number of patients eligible | Proportion of patients eligible | Number of patients eligible | Proportion of patients eligible | Number of patients eligible | Proportion of patients eligible | Number of patients eligible | Proportion of patients eligible | Number of patients eligible | ||
| Status quo | AbobotulinumtoxinA | 33% | 1,991 | 33% | 2,011 | 33% | 2,031 | 33% | 2,052 | 33% | 2,073 |
| OnabotulinumtoxinA | 52% | 3,137 | 52% | 3,169 | 52% | 3,201 | 52% | 3,233 | 52% | 3,266 | |
| IncobotulinumtoxinA | 15% | 905 | 15% | 914 | 15% | 923 | 15% | 933 | 15% | 942 | |
| New projections | AbobotulinumtoxinA | 33% | 1,991 | 43% | 2,620 | 53% | 3,262 | 63% | 3,917 | 73% | 4,585 |
| OnabotulinumtoxinA | 52% | 3,137 | 47% | 2,864 | 42% | 2,585 | 32% | 1,990 | 22% | 1,382 | |
| IncobotulinumtoxinA | 15% | 905 | 10% | 609 | 5% | 308 | 5% | 311 | 5% | 314 | |
Notes: Market research done by Ipsen Biopharm Ltd (unpublished data, October 2012).
Abbreviation: BoNT-A, botulinum toxin A.